OncoC4 announced the first patient dosing in a Phase 2 clinical trial evaluating the combination of ONC-392 and KEYTRUDA for the treatment of platinum-resistant ovarian cancer.
ROCKVILLE, MD, USA, December 30, 2022 (GLOBE NEWSWIRE), OncoC4 Corporation today announced, In a Phase 2 combined immunotherapy trial of a new generation anti-CTLA-4 antibody, ONC-392, and Merck's anti-PD-1 antibody, KEYTRUDA? (pembrolizumab), in patients with platinum-resistant ovarian cancer (PROC) (Presert-004), NCT05446298) has been activated and the first patient has been successfully dosed.
2024-08-24
